近日，北京中医药大学东直门医院王勇教授和广州中医药大学王伟教授团队在Medicine Plus上发表综述文章“Anthracycline-induced cardiotoxicity: emerging mechanisms and ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

CNS Pharmaceuticals (CNSP) announced the primary analysis of its clinical trial evaluating Berubicin, the first anthracycline demonstrated to ...

Fintel reports that on March 25, 2025, Maxim Group upgraded their outlook for Moleculin Biotech (NasdaqCM:MBRX) from Hold to ...

In this work, two-dimensional LC separation and peptide derivatization by a tandem mass tag (TMT) were used to assess the capability of μLC-MS/MS to reveal protein changes associated with the severe ...

The statement highlights that anthracycline chemotherapy and chest-directed radiotherapy have been well-studied cardiotoxic therapies and that modern radiotherapy, dose reductions, and use of ...

He required additional treatment with anthracyclines. He was monitored with cardio-oncology follow-up after every cycle of anthracycline and tolerated a cumulative 312 mg/m 2 therapy. The safety of ...

Q4 2024 Earnings Call Transcript March 24, 2025 Operator: Hello, and welcome to the Moleculin Biotech Fourth Quarter and Full ...

The safety profile continues to be favorable, including the absence of anthracycline related cardiotoxicity. Analysis of outcomes are ongoing, including advanced imaging review, PK, and clinical ...

Phase III IMvoke010 trial found that maintenance treatment with Tecentriq (atezolizumab) did not significantly improve ...

Berubicin showed clinically relevant outcomes comparable to Lomustine across multiple endpoints, but not a statistically significant difference in overall survival, the primary endpoint.The safety pro ...